Tarsus Pharmaceuticals (TARS) Gets a Buy from Barclays

1 day ago · Barclays analyst Balaji Prasad assigned a Buy rating to Tarsus Pharmaceuticals (TARS – Research Report) today and set a price target of $60.00. The company’s shares …

CouponFollow Extension

$60.00
OFF

Tarsus Pharmaceuticals (TARS) Gets A Buy From Barclays

2 weeks from now

1 day ago · Barclays analyst Balaji Prasad assigned a Buy rating to Tarsus Pharmaceuticals (TARS – Research Report) today and set a price target of $60.00. The company’s shares …

businessinsider.com

$60.00
OFF

Barclays Reaffirms Their Buy Rating On Tarsus Pharmaceuticals …

2 weeks from now

Oct 28, 2024 · Barclays analyst Balaji Prasad maintained a Buy rating on Tarsus Pharmaceuticals (TARS – Research Report) today and set a price target of $60.00. The company’s shares …

businessinsider.com

22%
OFF

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops …

2 weeks from now

19 hours ago · Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 32.22% and 11.34%, respectively, for the quarter ended September 2024. ... of 700,000 at …

yahoo.com

82%
OFF

Tarsus Pharmaceuticals, Inc. (TARS) - Yahoo Finance

2 weeks from now

PMVP PMV Pharmaceuticals, Inc. 1.7400. +4.82%. Find the latest Tarsus Pharmaceuticals, Inc. (TARS) stock quote, history, news and other vital information to help you with your stock …

yahoo.com

$48
OFF

Earnings Call: Tarsus Reports Record Sales For XDEMVY In Q3 2024

2 weeks from now

19 hours ago · Tarsus Pharmaceuticals, Inc. (TARS) announced robust third-quarter results for 2024, with a record $48 million in net product sales for XDEMVY, an eye care treatment for …

investing.com

22%
OFF

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue ...

2 weeks from now

1 day ago · Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 32.22% and 11.34%, respectively, for the quarter ended September 2024. ... Our experts picked 7 …

zacks.com

$63.00
OFF

Tarsus Pharmaceuticals (NASDAQ:TARS) Stock, Analyst Ratings, …

2 weeks from now

Buy. Highest Price Target 1. $63.00. Lowest Price Target 1. ... and Barclays on August 9, 2024, May 13, 2024, and May 10, ... The current price Tarsus Pharmaceuticals (TARS) is trading at …

benzinga.com

$5
OFF

Tarsus Pharmaceuticals (TARS) Gets A Buy From Barclays

2 weeks from now

May 8, 2024 · Barclays analyst Balaji Prasad assigned a Buy rating to Tarsus Pharmaceuticals (TARS – Research Report) today and set a price target of $5...

businessinsider.com

$51.60
OFF

Tarsus Pharmaceuticals (TARS) Stock Forecast & Price Target

2 weeks from now

2 days ago · According to the 7 analysts' twelve-month price targets for Tarsus Pharmaceuticals, the average price target is $51.60. The highest price target for TARS is $63.00, while the …

marketbeat.com

$0.00
OFF

Tarsus Pharmaceuticals (TARS) Earnings Date And Reports 2024

2 weeks from now

1 day ago · Tarsus Pharmaceuticals issued Q3 2024 earnings on November 13, 2024, reporting an EPS of $0.00, which beat the consensus estimate of -$0.90 by $0.90. With a trailing EPS of …

marketbeat.com

FAQs about Tarsus Pharmaceuticals (TARS) Gets a Buy from Barclays Coupon?

How much did Tarsus pharmaceuticals (Tars) earn in Q3 2024?

SA Transcripts 150.4KFollowers Follow Q3: 2024-11-13 Earnings Summary Play Call10-Q EPS of -$0.61 beats by $0.31 | Revenue of $48.12M(2,471.78% Y/Y)beats by $4.94M Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET ...

Is Tarsus Pharmaceuticals a good stock to buy?

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tarsus Pharmaceuticals with a $62.50 average price target, a 58.59% upside from current levels. In a report released on October 22, Oppenheimer also maintained a Buy rating on the stock with a $63.00 price target. ...

Where is Tarsus Pharmaceuticals Inc headquartered?

The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA. TARS | Complete Tarsus Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. ...

How much did Tarsus pharmaceuticals (Tars) lose?

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 32.22%. ...

What does Tarsus stand for?

Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) – The Company or Tarsus ...

What does Tarsus pharmaceuticals do?

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. ...